[1] New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the European Society of Hypertension Annual Meeting 2023. Retrieved June 27, 2023, from https://www.idorsia.com/media/news-details?newsId=3027113
[2] The Lancet and AHA late-breaking science session reports the resultsof Phase 3 study of aprocitentan. Retrieved June 27, 2023, from https://www.idorsia.com/documents/com/fact-sheets-presentations/221108_aprocitentan-aha-lancet-webcast.pdf